TABLE 1.
Clinical characteristics of the study subjects
| Subject | Age (yr) at first biopsy | Gender | HCV duration (yr)a | Alcohol useb | IDU frequencyc
|
Fibrosis stage
|
Fibrosis change (no. of stages) | Biopsy interval (mo) | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Biopsy 1 | Biopsy 2 | Biopsy 1 | Biopsy 2 | |||||||
| FP1 | 55 | M | 27 | 0 | 0 | 0 | 1 | 4 | 3 | 51 |
| FP2 | 40 | M | 23 | ++ | + | + | 1 | 6 | 5 | 53 |
| FP3 | 34 | M | 18 | + | ++ | +++ | 0 | 3 | 3 | 44 |
| FP4 | 42 | M | 25 | + | + | 0 | 1 | 4 | 3 | 47 |
| FP5 | 43 | M | 30 | + | 0 | ++ | 0 | 3 | 3 | 53 |
| SP1 | 43 | M | 22 | + | + | +++ | 0 | 0 | 0 | 51 |
| SP2 | 46 | M | 30 | 0 | 0 | 0 | 0 | 0 | 0 | 44 |
| SP3 | 47 | M | 34 | + | +++ | ++ | 1 | 2 | 1 | 44 |
| SP4 | 42 | M | 29 | ++ | + | 0 | 0 | 0 | 0 | 48 |
| SP5 | 40 | M | 23 | + | 0 | 0 | 1 | 0 | −1 | 44 |
| SP6 | 36 | M | 10 | ++ | + | ++ | 0 | 0 | 0 | 53 |
| SP7 | 47 | M | 30 | 0 | 0 | 0 | 0 | 1 | 1 | 49 |
| SP8 | 42 | M | 23 | + | 0 | 0 | 0 | 1 | 1 | 46 |
| SP9 | 43 | F | 16 | + | ++ | 0 | 1 | 2 | 1 | 48 |
| SP10 | 51 | F | 17 | + | + | + | 1 | 2 | 1 | 48 |
a
Duration of HCV infection, estimated using time from first injection drug use to first biopsy (9).
b
Proportion of semiannual visits at which the behavior was acknowledged: 0, none of visits; +, some but not all visits; ++, all visits.
c
Self-reported number of injection drug use (IDU) episodes during the preceding 6 months: 0, none; +, 1 to 100; ++, 101 to 500; +++, more than 500.